Internal Medicine, Hematology & Oncology · Las Vegas, NV
NPI
1376552745
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
7445 Peak Dr
Las Vegas, NV, 89128
Phone (702) 952-2140
Groups this clinician bills Medicare through
Medicare paid, 2024
$6.0M
472,423 services
Medicare patients, 2024
1,330
Average age 74
Drug cost, 2024
$6.5M
2,654 prescriptions
Company payments, 2025
$31K
From 33 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Anuradha R Thummala was code Q5110 (injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram), 74,940 times for 26 patients. In total Anuradha R Thummala billed 472,423 services in 215 codes, and Medicare paid $6.0M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-03-21.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| Q5110 Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram | Office | 74,940 | 26 | $0.22 | $16K |
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 43,500 | 70 | $2.29 | $99K |
| Q5101 Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | Office | 39,181 | 29 | $0.25 | $9,766 |
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 33,000 | 28 | $0.86 | $28K |
| Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 25,500 | 40 | $0.27 | $6,809 |
| J9271 Injection, pembrolizumab, 1 mg | Office | 23,401 | 30 | $44.56 | $1.0M |
| J1453 Injection, fosaprepitant, 1 mg | Office | 23,400 | 47 | $0.11 | $2,534 |
| J9263 Injection, oxaliplatin, 0.5 mg | Office | 15,490 | 16 | $0.05 | $832 |
| J0897 Injection, denosumab, 1 mg | Office | 12,180 | 95 | $20.17 | $246K |
| J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 10,440 | 18 | $39.58 | $413K |
| Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 7,500 | 67 | $0.10 | $772 |
| J1568 Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 4,320 | 25 | $36.94 | $160K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 4,088 | 143 | $0.09 | $360 |
| J9304 Injection, pemetrexed (pemfexy), 10 mg | Office | 3,131 | 11 | $45.59 | $143K |
| J0185 Injection, aprepitant, 1 mg | Office | 2,860 | 13 | $1.38 | $3,948 |
By year: 2022 $4.5M for 390,585 services; 2023 $5.1M for 452,233 services; 2024 $6.0M for 472,423 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 2,321 | 588 | $7.58 | $18K |
| 36415 Venipuncture Blood Collection | 2,020 | 583 | $8.56 | $17K |
| 80053 Clinical Chemistry | 1,612 | 550 | $10.34 | $17K |
| 82784 Immunoassay | 1,094 | 235 | $9.11 | $9,970 |
| 83550 Clinical Chemistry | 760 | 442 | $8.54 | $6,489 |
| 83540 Clinical Chemistry | 760 | 442 | $6.32 | $4,800 |
| 82728 Clinical Chemistry | 760 | 442 | $13.31 | $10K |
| 82378 Clinical Chemistry | 564 | 283 | $18.55 | $10K |
| 83615 Clinical Chemistry | 556 | 348 | $5.90 | $3,281 |
| 83521 Immunoassay | 358 | 145 | $16.92 | $6,059 |
Medicare prescription drug claims, 2024
In 2024, the drug Anuradha R Thummala prescribed most often to Medicare patients was Letrozole, with 339 prescriptions and refills. In total Anuradha R Thummala wrote 2,654 Medicare prescriptions that cost $6.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Letrozole Generic | 339 | 809 | 94 | $7,259 |
| Eliquis Apixaban | 335 | 463 | 70 | $268K |
| Acyclovir Generic | 145 | 256 | 33 | $2,203 |
| Folic Acid Generic | 96 | 284 | 34 | $1,259 |
| Levothyroxine Sodium Generic | 95 | 185 | 26 | $867 |
| Pantoprazole Sodium Generic | 77 | 117 | 23 | $579 |
| Exemestane Generic | 77 | 134 | 21 | $9,836 |
| Gabapentin Generic | 70 | 83 | 25 | $394 |
| Olanzapine Generic | 67 | 73 | 21 | $727 |
| Prednisone Generic | 62 | 73 | 22 | $242 |
| Lenalidomide Generic | 60 | 60 | Under 11 | $802K |
| Ondansetron Hcl Generic | 53 | 53 | 24 | $3,696 |
| Brukinsa Zanubrutinib | 52 | 52 | Under 11 | $718K |
| Anastrozole Generic | 51 | 139 | 15 | $890 |
| Pomalyst Pomalidomide | 45 | 45 | Under 11 | $917K |
Brand drugs: 770 claims; generic drugs: 1,884 claims; opioid claims: 45.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Anuradha R Thummala $31K ($31K in general payments such as food, travel and fees) from 33 companies. The largest payer was Exelixis Inc. with $6,962.
| Company | Payments | Amount |
|---|---|---|
| Exelixis Inc. EXEL | 24 | $6,962 |
| Gilead Sciences, Inc. GILD | 20 | $5,907 |
| AstraZeneca Pharmaceuticals LP AZN | 10 | $4,421 |
| Daiichi Sankyo Inc. 4568.T | 35 | $3,902 |
| Regeneron Healthcare Solutions, Inc. REGN | 3 | $2,923 |
| E.R. Squibb & Sons, L.L.C. BMY | 2 | $2,495 |
| Novartis Pharmaceuticals Corporation NVS | 17 | $1,930 |
| Stemline Therapeutics Inc. | 1 | $1,240 |
| Tempus AI, Inc TEM | 12 | $182 |
| Sobi, Inc SOBI.ST | 8 | $143 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.